NCT07564414ClinicalTrials.gov
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes
باختصار
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for…
المرحلة 3مطلوب 2,500 مشارك303 مواقع19 دولة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07564414فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-05-04; recorded start 2026-05-21
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 303 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,500 participants (target), run at 303 sites, across 19 countries.
How this score is built
- Enrolment34/40
2,500 participants (target)
- Site count25/25
303 sites
- Country count15/15
19 countries
- Planned duration7/10
Planned over about 23 months
- Sponsor scale9/10
Novo Nordisk A/S has led 320 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
الحالات
- Obesity
- Type 2 Diabetes
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 2,500 مشارك |
الجهة الراعية والمتعاونون
- Novo Nordisk A/S الجهة الراعية
الأذرع والتدخلات
- Cagrisema - dose level 1EXPERIMENTAL
Participants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks.
- Cagrisema - dose level 2ACTIVE_COMPARATOR
Participants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks.
- SemaglutideACTIVE_COMPARATOR
Participants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks.
التدخلات
- دواء Cagrisema
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
- دواء Semaglutide
Semaglutide will be administered subcutaneously.
مقاييس النتائج
مقياس النتيجة الأولي
Relative change in body weight
Measured as percentage (%).
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Relative change in body weight
Measured as %.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Change in Body Mass Index (BMI)
Measured as kilograms per square metre (kg/m\^2).
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve greater than or equal to (≥) 30% weight reduction
Measured as count of participants.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve ≥25% weight reduction
Measured as count of participants.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve greater ≥ 20% weight reduction
Measured as count of participants.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Change in waist circumference
Measured in centimetre (cm).
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Mean change in body weight
Measured in kilograms (kg).
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve a BMI less than (<) 30 kg/m^2
Measured as count of participants.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve BMI <27 kg/m^2
Measured as count of participants.
الإطار الزمني end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve normal BMI, defined as 18.5 lesser than or equal to (≤) BMI < 25 kg/m^2
Measured as count of participants.
الإطار الزمني At end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve a waist-to-height ratio < 0.53
Measured as count of participants.
الإطار الزمني At end of treatment (week 72)
مقياس النتيجة الثانوي
Ratio to baseline : Total cholesterol
Measured in terms of ratio.
الإطار الزمني From baseline (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Ratio to baseline : High density lipoprotein (HDL) cholesterol
Measured in terms of ratio.
الإطار الزمني From baseline (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Ratio to baseline : Low density lipoprotein (LDL) cholesterol
Measured in terms of ratio.
الإطار الزمني From baseline (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Ratio to baseline : Very low density lipoprotein ( VLDL) cholesterol
Measured in terms of ratio.
الإطار الزمني From baseline (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Ratio to baseline : Triglycerides
Measured in terms of ratio.
الإطار الزمني From baseline (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Ratio to baseline: Free fatty acids
Measured in terms of ratio.
الإطار الزمني From baseline (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Ratio to baseline : Non-HDL cholesterol
Measured in terms of ratio.
الإطار الزمني From baseline (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Change in Short-Form-36 Health Survey Version 2.0 (SF-36v2) physical Function
Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) physical function
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Change in glycated haemoglobin (HbA1c)
Measured in %-points.
الإطار الزمني From randomisation (week 0) to end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve HbA1c <6.5%
Measured as count of participants.
الإطار الزمني At end of treatment (week 72)
مقياس النتيجة الثانوي
Number of participants who achieve normal HbA1c <5.7%
Measured as count of participants.
الإطار الزمني At end of treatment (week 72)
مقياس النتيجة الثانوي
Number of treatment-emergent adverse events (TEAEs)
Measured in number of events.
الإطار الزمني From randomisation (week 0) to end of study (week 80)
مقياس النتيجة الثانوي
Number of treatment-emergent serious adverse events (TESAEs)
Measured in number of events.
الإطار الزمني From randomisation (week 0) to end of study (week 80)
التواريخ
| تاريخ البدء | 21 مايو 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 23 فبراير 2028 (تقديري) |
| الإتمام | 19 أبريل 2028 (تقديري) |
| أول نشر | 4 مايو 2026 (فعلي) |
| آخر تحديث | 30 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
موقع واحد قيد التجنيد
Argentina
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| OMI- Organización Médica de Investigación | Buenos Aires | نشط، دون تجنيد | |
| Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli | Buenos Aires | نشط، دون تجنيد | |
| Hospital Sirio Libanes | Buenos Aires | نشط، دون تجنيد | |
| Kynet Recoleta | Buenos Aires | نشط، دون تجنيد | |
| CEMEDIC | CABA | Buenos Aires | نشط، دون تجنيد |
| CEDIC Centro de Investigación Clínica | CABA | لم يبدأ التجنيد بعد | |
| CIPREC Arenales | CABA | نشط، دون تجنيد | |
| Centro Médico Viamonte SRL | CABA | نشط، دون تجنيد | |
| Centro de Investigaciones Metabólicas | Capital Federal | Buenos Aires | نشط، دون تجنيد |
| CICEMO- Consultorio (Av Directorio) | Ciudad Autónoma de Buenos Aires | Buenos Aires | نشط، دون تجنيد |
| Centro Médico Arsema | Ciudad Autónoma de Buenos Aires | Buenos Aires | نشط، دون تجنيد |
| Instituto Centenario | Ciudad de Buenos Aires | نشط، دون تجنيد | |
| Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de Julio | San Miguel de Tucumán | Tucumán Province | نشط، دون تجنيد |
| CEDIR - Centro de diagnóstico y rehabilitación Santa Fe | Santa Fe | نشط، دون تجنيد | |
| Sanatorio Norte | Santiago del Estero | نشط، دون تجنيد |
Australia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| University of Sunshine Coast - Vitality Village | Birtinya | Queensland | نشط، دون تجنيد |
| Emeritus Research Melbourne | Camberwell | Victoria | نشط، دون تجنيد |
| Sydney Clinical Trials | Campbelltown | New South Wales | نشط، دون تجنيد |
| Gosford Renal Research | Gosford | New South Wales | نشط، دون تجنيد |
| Sydney Cardiometabolic Centre | Liverpool | New South Wales | نشط، دون تجنيد |
| Hunter Diabetes Centre | Merewether | New South Wales | نشط، دون تجنيد |
| University of Sunshine Coast - South Brisbane | South Brisbane | Queensland | نشط، دون تجنيد |
Austria
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Medical University of Graz | Graz | نشط، دون تجنيد | |
| Ordination Winhofer-Stöckl | Mattersburg | نشط، دون تجنيد | |
| Fließer-Görzer [Ordination] | Saint Stefan | نشط، دون تجنيد | |
| Universitätsklinikum AKH Wien | Vienna | نشط، دون تجنيد | |
| Klinik Landstraße | Vienna | نشط، دون تجنيد | |
| Ordination Dr. Günter Sokol | Vienna | نشط، دون تجنيد | |
| Klinik Hietzing 3. Med. Abt. | Vienna | نشط، دون تجنيد | |
| Itariu [Ordination] | Vienna | نشط، دون تجنيد |
Belgium
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Anima Research Center | Alken | نشط، دون تجنيد | |
| Cliniques universitaires Saint-Luc | Brussels | لم يبدأ التجنيد بعد | |
| KORMONT | Kluisbergen | نشط، دون تجنيد | |
| CHU Tivoli | La Louvière | نشط، دون تجنيد | |
| MECLINAS | Mechelen | نشط، دون تجنيد | |
| AZ Delta - Roeselare | Roeselare | نشط، دون تجنيد | |
| KORMONT | Zwalm | نشط، دون تجنيد |
Bulgaria
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| MC For Life EOOD | Burgas | نشط، دون تجنيد | |
| MC Kazanlak EOOD | Kazanlak | نشط، دون تجنيد | |
| Medical center Medi City 21 OOD | Kyustendil | نشط، دون تجنيد | |
| OCSOMCE - Dr. Albena Dinkova EOOD | Pleven | نشط، دون تجنيد | |
| AIPSMCEMDID - Dr. Georgi Levterov EOOD | Plovdiv | مكتمل | |
| DCC Sveti Georgi EOOD | Plovdiv | نشط، دون تجنيد | |
| Hipocrat 9 - Dr. Rumyana Boykova - Draganova - AISPEMD EOOD | Sofia | نشط، دون تجنيد | |
| DCC XX - Sofia EOOD, Endocrinology | Sofia | نشط، دون تجنيد | |
| MC Diamedical - 2013 OOD, Sofia | Sofia | نشط، دون تجنيد | |
| Medical Centre Medical Arts Medico-dental centre | Sofia | نشط، دون تجنيد | |
| DCC XXV Sofia EOOD, Endocrinology Consulting room | Sofia | مكتمل | |
| UMHAT Prof. Dr. Stoyan Kirkovich AD | Stara Zagora | نشط، دون تجنيد | |
| AIPSMC Dr. Evelina Zlatanova EOOD | Varna | نشط، دون تجنيد |
يُدرَج 253 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.
يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.